Overview

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

Status:
NOT_YET_RECRUITING

Trial end date:
2027-04-30

Target enrollment:

Participant gender:

Summary

This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Kahr Bio Australia Pty Ltd

Collaborator:

Novotech (Australia) Pty Limited

Treatments:

atezolizumab
HMPL-013